ZYBERNO
Stock Report
Updated Sep 1, 2026

Evommune, Inc. (EVMN)

Healthcare • NYSE

$13.23

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
Evommune, Inc. (EVMN) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.06x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-27.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Evommune, Inc. (EVMN) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.23
Market Cap:$478.07M

Valuation Multiples (2)

P/B Ratio:1.72x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$425.72M

Price Action & Momentum (1)

% of 52-Week High:39.8%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.6%
Fundamental Growth Rate (g):-0.2%

Margin Analysis (1)

Ebitda Margin:-619.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:11.68x
Quick Ratio:11.68x
Cash Ratio:3.43x

Leverage Analysis (3)

Debt To Equity Ttm:0.06x
Debt-to-Equity Ratio:0.06x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:186,759,000.00
Cash And Cash Equivalents:60,034,000.00
Long Term Debt:$6.44M
Net Debt:-$52.36M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$13.00M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$81.07M

Bottom Line Performance (3)

-$68.87M
Income Before Tax:-$68.87M
Ebitda Ttm:-80,471,000.00

Operating Expenses (5)

Operating Expenses:34,895,000.00
R And D Expense:26,412,000.00
Sga Expense:8,483,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-619.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$301.95M
Current Assets:$204.25M
Ppe Net:1,650,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:24,361,000.00
Current Liabilities:17,487,000.00
Long Term Debt:$6.44M
Short Term Debt:$1.24M

Equity & Capital (3)

Equity:$277.59M
Retained Earnings:-$275.01M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,044,000.00

Special Items (2)

Contract Liabilities:3,000,000.00
Stock Based Compensation:4,598,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$76.44M-$76.68M

Investment Activities (1)

Investing Cash Flow:-$85.36M

Financing Activities (3)

Financing Cash Flow:$117.11M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:117,200,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.91

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.36
Operating Cash Flow Per Share:-$2.12

Book Value & Capital (2)

Book Value Per Share:$7.68
Cash Per Share:1.66

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.06x
Working Capital Turnover Ttm:0.07x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:141.62
Cash Conversion Cycle:-2,139.62
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.6%
Fundamental Growth Rate (g):-0.2%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:EVMN
Company Name:Evommune, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:36.14M
Shares Outstanding Basic:36.14M
Shares Outstanding Diluted:36.14M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:36:14 UTC
Data Timestamp:2026-09-01T12:36:14.097188
Scroll to Top